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INTRODUCTION
Pathologic aerophagia denotes the swallowing of excessive
volumes of air, which causes various gastrointestinal symp-
toms, and is a clinical entity that simulates gastrointestinal
motility disorders (1). Little information is available about
the effectiveness of different therapies in pathologic childhood
aerophagia (PCA) (2), and the management is largely reassur-
ance for patients with psychological stresses (PS) (1-5). In
patients with severe to profound mental retardation (MR)
and massive bowel distention, the placement of a percuta-
neous endoscopic gastrostomy (PEG) catheter, which can be
used to deflate, can prevent the complications of volvulus or
perforation (6, 7).
Although PCA with PS is known as a benign disorder,
38.1% of patients have a symptom duration exceeding 12
months before diagnosis (8). Also, although reassurance and
behavior therapies are potential treatments that can alleviate
symptoms in aerophagia, only 50% of patients who had expe-
rienced short-term symptom improvement after behavior
therapy maintained these improvements during a long-term
follow up (8 months later) (2). Therefore, reassurance and
behavior therapy may not be the ideal treatment for aerophagia.
In the PCA patients with PS, based on our videofluorosco-
pic investigations, we observed that the pathology of aeropha-
gia seems to be due to reflex-induced swallowing due to un-
known factors with paroxysmal openings of the upper esopha-
geal sphincter, without the oro-pharyngeal swallowing move-
ment sequences, followed by air swallows. We also observed
in 5 PCA patients that these reflex-induced paroxysmal open-
ings subsided after intravenous low dose benzodiazepine ad-
ministration. Therefore, we agreed to try clonazepam, a ben-
zodiazepine that is structurally related to chlordiazepoxide
hydrochloride, to treat PCA with PS.
The treatment of pathologic aerophagia is rarely discussed
in the literature, and few articles have been written about
aerophagia in childhood (1, 2, 5-7). Here, we analyzed and
evaluated the effects of clonazepam on the management of
PCA with PS.
MATERIALS AND METHODS
Study population
We retrospectively analyzed the data from 22 consecutive
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The treatment of pathologic aerophagia has rarely been discussed in the literature.
In this retrospective study, the authors investigated the effects of clonazepam on the
management of pathologic childhood aerophagia (PCA) with psychological stress-
es (PS), but not with mental retardation. Data from 22 consecutive PCA patients
with PS (aged 2 to 10 yr), who had been followed up for over 1 yr, were reviewed.
On the basis of videolaryngoscopic views, the authors observed that the pathology
of aerophagia was the result of reflex-induced swallowing with paroxysmal openings
of the upper esophageal sphincter due to unknown factors and also observed that
these reflex-induced openings were subsided after intravenous low dose benzodi-
azepine administration. Hence, clonazepam was administered to treat paroxysmal
openings in these PCA patients with PS. Remission positivity was defined as symp-
tom-free for a consecutive 1 month within 6 months of treatment. The results of treat-
ment in 22 PCA patients with PS were analyzed. A remission positive state was
documented in 14.3% of PCA patients managed by reassurance, and in 66.7% of
PCA patients treated with clonazepam (p=0.032). Thus, clonazepam may produce
positive results in PCA with PS. Future studies by randomized and placebo-con-
trolled trials are needed to confirm the favorable effect of clonazepam in PCA. 
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patients diagnosed with PCA patients with PS (9 female, 13
male; aged 2 to 10 yr), without severe to profound MR from
March 1995 to July 2004. Patients were followed up for over
1 yr. They were recruited from the inpatient and outpatient
units at the Dongsan Medical Center, Keimyung University
School of Medicine. Informed consent was obtained from all
parents of children treated with clonazepam, and all study
procedures and medications were approved by the Keimyung
University Institutional Review Board. Data were collected
by reviewing medical charts, and followings were recorded and
analyzed; age, underlying psychological stress factors, response
and remission rate to treatments, and the effect of clonazepam.
Clinical assessments of mental retardation were performed
using the Denver Developmental Screening Test or the Social
Maturity Scale. Psychological stress factors were identified
using the Stressful Life-Change Event Scale (9). Parents pro-
vided a rating of stress in the patient’s environment.
Fluoroscopic diagnosis of pathologic aerophagia
A diagnosis of pathologic aerophagia was made if the ob-
served symptomatic abdominal distention was due to the
swallowing of air, as confirmed by videofluoroscopy, and if
it was not attributable to any gastrointestinal disease, i.e.,
mechanical intestinal obstruction, chronic intestinal pseudo-
obstruction, bacterial overgrowth, Hirschsprung’s disease, or
malabsorption. These pathologies were considered initially
and then ruled out by clinical findings and progress, and
according to bowel transit times using sitz marker, gastro-
fiberscopic mucosal biopsy, or other tests as needed. A diag-
nosis of pathologic aerophagia, based on the videofluorosco-
pic observations, was defined as the presence of reflex-induced
swallowing due to unknown factors with paroxysmal open-
ings of the upper esophageal sphincter, followed by air swal-
lows, but without oro-pharyngeal swallowing movement
sequences (8). 
Assignment of the two management groups
In PCA patients with PS, parents were advised to choose
between two management protocols (reassurance or clonaze-
pam treatment) for PCA. Accordingly, patients were assigned
into two management groups; a reassurance group (7 patients)
and a clonazepam group (15 patients). We performed an open-
labeled trial with clonazepam only in PCA patients with
parental consent and compared the effect of clonazepam in
this group with findings in the reassurance group. 
Trial of clonazepam and reassurance
Benzodiazepine is a commonly used medication for myo-
clonus-like paroxysmal movements (10). In the present study,
we injected low dose of diazepam (1-3 mg) intravenously in
5 PCA patients with PS under videofluoroscopic observation.
Paroxysmal openings subsided a few minutes after injection,
but sedation was not induced. These findings were recorded
on a videotape and thoroughly analyzed by a consensus among
the authors. Hence, we administered oral clonazepam (Riv-
otril
�, Korea Roche) to PCA patients with given parental con-
sent, but unfortunately this was not placebo-controlled. At
a body weight of less than 30 kg, the initial dosage was 0.025
mg/kg/day in two divided doses. Doses were incremented by
0.025 mg/kg every 3 to 5 days as needed; the usual mainte-
nance dosage was 0.1 mg/kg. For body weights exceeding
30 kg, the initial and maintenance dosages were 1.5 mg daily
in two divided doses. No patient had a clonazepam-contraindi-
cating disease or condition, such as, liver disease, renal impair-
ment, or narrow-angle glaucoma. Blood concentrations were
monitored monthly, and parents were informed of possible
side effects and were instructed to carefully observe patients.
Clonazepam was prescribed for 1 month and discontinued if
the response was negative. However, if the response was posi-
tive, it was continued for an additional 4 months or to symp-
tom-free for a consecutive 1 month. Clonazepam treatment
was discontinued by tapering over an additional 1 month.
Reassurance of patients and parents was performed on every
visit at an out-patient clinic by a pediatric gastroenterologist,
who addressed the clinical characteristics and natural course
of the pathologic aerophagia and periodically assessed clini-
cal symptoms and disease progress, and by a pediatric psy-
chiatrist, who rated mental retardation, identified psycholog-
ical stress, and provided psychiatric support to patients and
patients’ family members in terms of coping with stress.
Definition of response and remission 
To evaluate treatment effects, we defined response posi-
tive as being symptom-free for a consecutive 1 week within
1 month of treatment and remission positive as being symp-
tom-free for a consecutive 1 month within 6 months of treat-
ment. Interviews were conducted to parents at out-patient
clinic at intervals of 1 week during the first month of treat-
ment, and thereafter at 2-week intervals. Each parent ob-
served and recorded; 1) abdominal distention during the late
evening, 2) symptoms (abdominal discomfort, increased fla-
tus, and increased flatus while sleeping, and visible or audi-
ble air swallowing sound) during the late evening, and 3)
bowel sounds as determined by ear on the patient’s abdomen
during the late evening. In case of increased abdominal dis-
tention, a positive clinical symptom and increased bowel
sound (8), we defined that the symptom-free state had not
been achieved during that day. 
Statistical analysis
Fisher’s exact test was used for the statistical analysis. Sta-
tistical significance was accepted at p<0.05. Data were pre-
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RESULTS
Age distribution and psychological stress factors 
The average age of the 22 PCA patients was 5.9±2.6 yr
(range, 2-10 yr). There were no significant differences between
the two treatment groups in terms of age, sex, or symptom
duration. PCA was precipitated by the following psycholog-
ical stress factor; school or preschool entrance (31.8%), birth
of siblings (22.7%), a working mother (13.6%), divorce of
parents (9.1%), being scolded (4.5%), a mother’s psychosis
(4.5%), hospital admission (4.5%), toilet training (4.5%),
and trouble with a sibling (4.5%).
Response and remission by treatments
None of the patients treated with clonazepam showed any
side effect. The treatments administered to the 22 PCA with
PS patients were reassurance (n=7) and clonazepam (n=15).
None of PCA patients managed by reassurance achieved a
response positive state, but 40.0% of PCA patients treated
with clonazepam did (p=0.067). A remission positive state
occurred in 14.3% of PCA patients managed by reassurance
and in 66.7% of PCA patients treated with clonazepam (p=
0.032) (Table 1). No recurrence of aerophagia occurred in the
reassurance or clonazepam group that achieved a remission
positive state during the 6 months of follow-up after remission.
DISCUSSION
A review of the literature (1-8) shows that the main under-
lying associations of pathologic aerophagia are severe to pro-
found mental retardation and identified psychological stresses.
In PCA patients with identified PS, the psychological stress
factors are problems that are frequently encountered during
child development. Moreover, patients are otherwise healthy
children, but are highly sensitive individuals (4). Environ-
mental factors such as stress and attention seeking have been
suggested to be the causes of aerophagia (3, 4). 
When the movement of a bolus from the oral cavity to the
pharyngeal space triggers the swallowing reflex or response,
the subsequent physiological events leading to the esophageal
phase are mainly controlled by the anatomophysiological
network, designated the ‘central pattern generator’ of swal-
lowing. When this is triggered, sequential muscle activity
begins in an orderly fashion from the facial- and trigeminal-
innervated muscles to the cricopharyngeus sphincter muscle
and striated esophageal muscles (11). Innervation of the cri-
copharyngeus muscle has been the subject of much debate.
The consensus view is that the cricopharyngeus muscle has
a dual innervation by the pharyngeal plexus of the vagus nerve
(tenth cranial nerve) and the recurrent laryngeal nerve (12).
Our observations indicate the possibility of that pathologic
aerophagia as a reflex-induced movement of the cricopharyn-
geus sphincter may be induced by any pathology of the neu-
rological swallowing sequence. Unfortunately, we had not
performed submental muscle electromyography or cricopha-
ryngeal sphincter electromyography to evaluate abnormali-
ties of ‘central pattern generator’. The neurophysiology of
swallowing in patients with pathologic aerophagia must be
further evaluated.
We suspect that pathologic aerophagia may stem from psy-
chogenic movement disorders, which means that non-epilep-
tic physiological myoclonus-like movement may be induced
by anxiety (9, 13). Therefore, we undertook to trail clonaze-
pam for the treatment of PCA. In patients with identified PS
factors, no response was achieved in any of the reassurance
group patients, but was achieved in 40.0% of the clonazepam
group patients. This result was of borderline significance, but
it suggests that reassurance itself may not induce a response.
Remission occurred in 14.3% of patients managed by reas-
surance, and in 66.7% of patients treated with clonazepam.
These observations show, although management by reassur-
ance itself may improve pathologic aerophagia in patients
with identified psychological stresses, that clonazepam treat-
ment is significantly more effective at inducing remission of
pathologic aerophagia than reassurance. However, clonazepam
may affect centrally to relieve the patient from stress and also
may exert a placebo effect. These effects may induce a positive
response or remission to some degree in patients with PCA.
The background of psychophysiology and of neurological dis-
orders in patients with pathologic aerophagia must be further
evaluated, and in addition, the relationship between the cau-
sative role of psychological stresses and reflex-induced swal-
lowing with paroxysmal upper esophageal sphincter openings
should be further evaluated.
In conclusion, pathologic aerophagia appears to be due to
the reflex-induced swallowing from unknown factors. More-
over, this study shows that in PCA patients with PS, clon-
azepam may achieve positive results. Unfortunately, a ran-
domized trial could not be performed due to the low inci-
dence of PCA. To the best of our knowledge, this is the first
trial of clonazepam in PCA. Future study based on a rando-
*p=0.067, 
� p=0.032.
*Defined as being symptom-free for a consecutive 1 week within 1 month
of treatment. 
� Defined as being symptom-free for a consecutive 1 month
within 6 months of treatemnt.
Response*
Positive Negative
Remission
�
Positive Negative
Ressaurance 0 (0.0) 7 (100.0) 1 (14.3) 6 (85.7)
(n=7) (%)
Clonazepam 6 (40.0) 9 (60.0) 10 (66.7) 5 (33.3)
(n=15) (%)
Table 1. The results of response and remission according to the
treatments of children with pathologic childhood aerophagia
with identified psychological stress factormized, placebo-controlled trial is needed to confirm the favo-
rable effect of clonazepam in PCA. 
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